ASCO 2018

Viewing 1-20 of 31 articles

ASCO 2018: Measurable Immunologic Changes and Improved Clinical Activity in mRCC with Nivolumab + Bevacizumab or Nivolumab + Ipilimumab

ASCO 2018: CABOPRE: Phase II Study of Cabozantinib Prior to Cytoreductive Nephrectomy in Locally Advanced and/or Metastatic Renal Cell Carcinoma

ASCO 2018: KEYNOTE-564: A Phase 3, Randomized, Double Blind, Trial of Pembrolizumab in the Adjuvant Treatment of Renal Cell Carcinoma

ASCO 2018: Nivolumab for Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma: A Single-Institution Experience

ASCO 2018: Effectiveness and Safety of Pazopanib and Everolimus in a Changing Treatment Landscape: Interim Results of the Non-Interventional Study PAZOREAL

ASCO 2018: Prospective, Multinational, Observational Study of Real-World Treatment Outcomes with Pazopanib in Patients with Advanced or Metastatic Renal Cell Carcinoma (Principal Study)

ASCO 2018: Role of Surgery in Management of High-Risk Renal Cell Cancer

ASCO 2018: Systemic Therapy in Management of High-Risk Renal Cancer

ASCO 2018: Optimizing Systemic Therapy in Advanced Renal Cell Carcinoma

ASCO 2018: Patient-reported Outcomes in IMmotion151: Atezolizumab + Bevacizumab vs Sunitinib in Treatment Naive mRCC

ASCO 2018: RESORT - A Randomized, Open Label, Multicenter Phase 2 Study, to Evaluate the Efficacy of Sorafenib in Patients with mRCC after a Radical Resection of the Metastases

ASCO 2018: Sunitinib Alone Shows Non-inferiority Versus Standard of Care in mRCC - The CARMENA Study

ASCO 2018: A Pilot Randomized Study Evaluating Nivolumab or Nivo + Bevacizumab or Nivo + Ipilimumab in Patients with Metastatic Renal Cell Carcinoma Eligible for Cytoreductive Nephrectomy, Metastasectomy or Post-treatment Biopsy

ASCO 2018: CARMENA: Cytoreductive Nephrectomy Followed by Sunitinib vs. Sunitinib Alone in Metastatic Renal Cell Carcinoma - Results of a Phase III Noninferiority Trial

ASCO 2018: Gut Microbiome Composition to Predict Resistance in Renal Cell Carcinoma Patients on Nivolumab

ASCO 2018: Correlation of Degree of Tumor Immune Infiltration and Insertion-and-Deletion Burden with Outcome on Programmed Death 1 Therapy in Advanced Renal Cell Cancer

ASCO 2018: Prospective Phase II Multi-Center Study of Individualized Axitinib Titration for Metastatic Renal Cell Carcinoma After Treatment with PD-1 / PD-L1 Inhibitors

ASCO 2018: A Phase 3, Randomized, Open-label Study of Nivolumab Combined with Cabozantinib vs Sunitinib in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

ASCO 2018: PROSPER: A Phase III Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy

ASCO 2018: A Randomized Phase 2 Trial of Pazopanib vs. Temsirolimus in Patients with Advanced Clear-Cell Renal Cell Carcinoma with Intermediate or Poor-risk Disease (The TemPa Trial)

1
2